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BCG Bacillus Calmette-Guerin (tuberculosis vaccine)
CFU colony forming units
CI (95% CI) confidence interval
CMI cell-mediated immunity
CoR correlate of risk (Qin et al. terminology)
E-IPV enhanced inactivated polio vaccine 
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HbOC Haemophilus influenzae type b oligosaccharide conjugate vaccine
HI haemagglutination inhibition
Hib Haemophilus influenzae type b
ICC Intraclass correlation coefficient
ICH International Conference on Harmonization
IFN-y Interferon gamma
Ig immunoglobulin
IM immune (or immunological) marker
IPD  invasive pneumococcal disease 
IPV inactivated (killed) polio vaccine
LD50 lethal dose, 50%
LTT lymphocyte transformation test
MLSA Mycobacterium leprae soluble antigen 
Mtb Mycobacterium tuberculosis
viii
OMP(C) outer membrane protein (complex)
OPA opsonophagocytic antibodies 
OPV oral polio vaccine
PPD purified protein derivative
PRN plaque reduction neutralization (e.g. measles antibody assay)
PRP polyribosyl ribitol phosphate (H. influenzae polysaccharide)
PT pertussis toxin
PTE proportion of treatment effect explained
PTN pertactin (B. pertussis antigen)
RCT randomized controlled trial
SBA serum bactericidal antibody (rSBA: SBA with rabbit complement)
SD standard deviation
SES socioeconomic status
SoP surrogate of protection (Qin et al. terminology)
VE vaccine efficacy (or effectiveness), defined as (1 – Rv/Rnv) where Rv 
and Rnv are outcome risks in similarly exposed vaccinated and non-
vaccinated individuals, respectively 
VECE vaccine efficacy (or effectiveness) based on clinical endpoint
VEIM  Vaccine efficacy (or effectiveness) based on immunological 
endpoint
VZV varicella-zoster virus
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The ability to assess the protective efficacy of a vaccine by measuring the proportion 
of vaccinees who generate a particular immune response, without having to measure 
clinical outcomes, has significant advantages. The availability and quality of such 
substitute endpoints1 are important for vaccine development, licensure and effectiveness 
monitoring. A better understanding of the interrelationships between vaccination, 
the immune response, protection, and clinical outcomes is thus of interest not only 
to regulatory authorities but also to microbiologists, immunologists, epidemiologists 
and statisticians.
This is a complex and controversial topic, and many aspects need clarification. 
Although regulatory bodies have drawn up definitions for “correlates” and “surrogates” 
of protection for the purpose of licensure, these terms are not used consistently among 
regulators, nor in the broader literature. Different study designs, each with their strengths 
and weaknesses, have been used to evaluate immunological substitute endpoints of 
vaccine-induced protection. Various statistical tools have been developed to evaluate 
these endpoints, but few epidemiologists are familiar with the details of these methods. 
Immunological substitute endpoints can be relative or absolute quantities, and further 
information is needed on how they are affected by factors such as the challenge dose, 
the mechanism of action of the vaccine, the environment, or host characteristics. 
This document presents an overview of definitions and methods relating to studies 
of substitute endpoints. It aims to facilitate communication and to encourage the 
development of a broad research agenda on the issue. Although the greatest interest 
in this topic currently relates to vaccines, immunological correlates of protection have 
far-reaching implications for passive protection (maternal immunity and immunoglobulin 
prophylaxis), risk screening (e.g. tuberculin or rubella antibody testing in pregnant 
women) as well as for a basic understanding of pathogenesis and immunity. 
1.1 Definitions
Substitute endpoints have been discussed widely in the epidemiological literature 
in general and for vaccines in particular. Terms used include correlate of protection, 
surrogate of protection, immune marker of protection, correlate of risk, proximal endpoint, 
distal endpoint, intermediate endpoint, protection endpoint, and clinical endpoint. 
Authors and regulatory agencies use these terms with different definitions and nuances, 
associated with particular contexts. Annex 1 summarizes the major usage of terminology 
in the literature, a simplified schema of which is presented in Figure 1.
1 In this document, substitute endpoint is a general term including correlates and surrogates of 
protection, or “intermediate endpoints” – in other words, quantities that may be measured instead 
of the clinical endpoint (i.e. disease) of ultimate interest. 
1. Introduction
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Vaccines are given primarily to protect against disease, though protection against 
infection and even infectiousness may also be important effects. The implication of 
different clinical endpoints (infection, infectiousness, disease) are discussed later in 
this document, but we will, for simplicity, refer in general to protection against disease. 
Protection is evident, and measured, in terms of reduction in risk of the clinical endpoint 
of interest. Thus, by convention the (protective) efficacy of a vaccine (VE) is defined as 
the percent reduction in risk of (for example) disease amongst vaccinated individuals 
compared to equally exposed unvaccinated individuals, or VE = (Rnv - Rv)/(Rnv), 
where Rnv and Rv represent incidence risk or rate of disease in non-vaccinees and in 
vaccinnees respectively. For many reasons (cost, time, ethics…), the enumeration of 
clinical endpoints is difficult, and thus there is a motive to find and use simpler substitute 
(eg. immunological) endpoints in order to evaluate vaccines. 
Figure 1. Simple illustration of the induction of  
protective immunity by a vaccine
Vaccine Immune marker (IM-1)substitute end point
Immune marker (IM-2)
substitute end point
Protection
Exposure or 
infection
Clinical endpoint 
(disease)
Arrows imply direct causal relationships
1.1.1 Correlates and surrogates 
In Figure 1, protection is illustrated as the process which interrupts the pathway between 
“exposure or infection” and “clinical endpoint (eg. disease)”. This is meant to cover 
both the prevention of infection among exposed ndividuals, and the prevention of 
disease among infected individuals. Distinguishing between these mechanism is often 
not possible. 
IM-1 and IM-2 represent two sorts of intermediate or substitute immune markers 
involved in, or influenced by the relationship between vaccination and protection. 
As drawn, both IM-1 and IM-2 should change (i.e. appear, or increase in concentration) 
in the course of a vaccine’s induction of protection. Both are thus correlates of 
protection, as they should be statistically associated with vaccine-induced protection. 
This definition of a correlate as an attribute that is statistically associated with an 
endpoint (without the association necessarily being causal) is consistent with widespread 
usage in the epidemiological and statistical literature (1). 
IM-1 is represented on the direct arrow line between vaccine and protection, 
indicating that it is on the direct causal pathway: the vaccine induces protection via 
a mechanism involving IM-1. Many authors restrict the word surrogate to what is 
represented by IM-1 in this diagram, and this paper follows their lead (2–3). 
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IM-2, on the other hand, is not on the causal pathway between vaccination and 
protection – it represents something that happens as a consequence of being vaccinated, 
but which is not itself involved in protection. It is a correlate, but not a surrogate. 
By this convention, all surrogates are correlates, but not all correlates are surrogates 
(2). These are the senses used in this document. 
Two qualifications are necessary. First, the distinction based on causal mechanisms is not 
always as simple as represented in Figure 1, and it is easier to establish a correlate than 
a surrogate. Second, other conventions are followed by prominent contributors to the 
literature and major regulatory agencies, who use the terms differently (see Annex 1). 
Until the subject matures appreciably beyond its current state, readers need to be aware 
of the variety of usages of the terms, and authors need to clarify their terms carefully. 
1.1.2 Protection 
In the context of vaccines, protection implies an immunological mechanism to prevent 
or to reduce severity of infection or disease. The mechanism can involve both humoral 
and cellular arms of the immune system. Many aspects of these mechanisms are 
not yet understood. Protection is complex, not only in its mechanism, but also in 
its manifestation. It may be complete, such that a protected individual suffers no ill 
consequences whatsoever if exposed to infection. It may be incomplete, implying that 
the severity of the consequences of the disease is reduced. (The term partial protection 
is sometimes used for this state, but is also used in a different way for vaccines, 
as discussed in Section 6.1.2). Or it may be situation-dependent, related for example 
to the environment or to exposure dose. These nuances complicate the evaluation 
of vaccines either directly, with disease reduction outcomes, or through substitute 
immunological endpoints, be they correlates or surrogates. These issues are addressed 
later in this review. At first, however, we assume that protection is a binary variable – 
i.e. that individuals are either (completely) protected or not. 
Correlates of vaccine-induced protection: methods and implications4
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The validation and interpretation of immune markers as substitute endpoints for 
vaccine-induced protection depend on their relationships with the vaccine and with 
the clinical endpoint. Causal diagrams help to clarify these relationships, as shown 
below.
2.1 Single pathway with one immune marker
The simplest situation is a single pathway in which all the effect of the vaccine on the 
clinical endpoint is mediated through a single immune marker (IM-3), as in Figure 2. 
The implication here is that the immune marker is both necessary and sufficient for 
the vaccine to provide protection. Such a marker satisfies the strictest criteria for a 
surrogate.
Figure 2. Single pathway with one immune  
marker between vaccine and clinical endpoint
Vaccine Immune marker(IM-3) (Protection)
Exposure or 
infection
Clinical endpoint
An example of such a single pathway is seen in data relating to antibody to influenza 
Weiss strain A as an immune marker for protection against hospitalization with influenza 
(described more fully in Section 4.1.1 below) (4). 
2.2 Two or more immune markers
If multiple markers are influenced by a vaccine, any one of them may or may not be 
necessary or sufficient for protection. There are several possible circumstances. 
2. Implications of different 
immunological mechanisms
Correlates of vaccine-induced protection: methods and implications6
(i)  A series of immune markers fully explains the observed protective effect 
of a vaccine
If clinical protection occurs only when a combination of immune markers is 
present and not when any element of the combination is missing, this suggests that all 
elements are necessary for protection as successive steps of a single causal pathway, 
as in Figure 3. An example of this could be a cytokine cascade that is initiated in response 
to vaccination (except that cytokines are not specific for particular infections). As each 
marker is necessary, provided it is specific to a particular infection, it would satisfy the 
strict criterion for a surrogate.
Figure 3. Single pathway with several immune markers
Vaccine IM-4 (Protection)
Exposure or 
infection
Clinical endpoint
IM-5
(ii)  Immune markers are protective independently of one another
If clinical protection occurs when either one or another marker is present, this suggests 
that the markers belong to distinct pathways, as in Figure 4. Either immune marker can 
be sufficient for protection, but one may be more important than the other. 
Figure 4. Multiple immune response pathways 
Vaccine (Protection)
Exposure or 
infection
Clinical endpoint
IM-6
(e.g. Antibody X)
IM-5
(e.g. CMI)
CMI, cell-mediated immunity
Variations on this theme are possible, as illustrated in Figure 5. 
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Figure 5. Multiple immune response pathways  
between vaccine and clinical endpoint
Vaccine (Protection)
Exposure or 
infection
Clinical endpoint
IM-8
(e.g. Antibody X)
IM-9
(e.g. CMI)
EXAMPLE
Several studies provide evidence that specific serum neutralizing antibodies are protective against 
measles. For example, maternal antibody protects against measles, and a study by Chen et al. (5) helped 
to derive a level of antibody associated with protection against typical clinical measles at the individual 
level (PRN >120 mIU/mL). However, other studies have shown that patients with agammaglobulinaemia 
can clear measles infection, whereas individuals with certain cellular immune deficiencies may develop 
severe disease. This is indirect evidence of the importance of cell-mediated immunity in protection against 
measles. Further evidence for the involvement of multiple pathways is added by the good correlation 
between antibody and lymphoproliferative response in vaccinated patients (6).
An important issue with multiple causal pathways is how to apportion the protection to 
each mechanism (as discussed below). Also, one of the pathways may not be observed 
or may be difficult to measure. The validation of such a hidden “marker” as a substitute 
endpoint can be challenging. 
(iii)  At least one immune marker has no role in protection
There are situations in which an immune marker is affected by a vaccine, e.g. it may 
be a collateral effect of the vaccine, but may be completely unrelated to protection or 
the clinical endpoint (Figure 6). 
Figure 6. Immune marker as a collateral effect  
of the vaccine but unrelated to protection
Vaccine (Protection)
Exposure or 
infection
Clinical endpoint
IM-10
IM-11
Another possible mechanism is one in which a marker (Figure 7, IM-12) is not protective 
against the clinical endpoint, but is associated with a marker on the protective pathway 
induced by the vaccine (IM-13).
Correlates of vaccine-induced protection: methods and implications8
Figure 7. Immune marker induced by a step on the causal  
pathway but not involved in protection
Vaccine (Protection)
Exposure or 
infection
Clinical endpoint
IM-12
IM-13
IM-13 may or may not be observed. If IM-12 is a necessary product of IM-13, 
and if the association between IM-12 and IM-13 is strong, there will be a statistical 
association between IM-12 and the vaccine and between IM-12 and the clinical endpoint. 
This means that IM-12 could accurately predict the vaccine’s efficacy, and may be 
useful for vaccine development and licensure . Mere statistical validation of IM-12 
as a substitute endpoint will fail to detect that IM-12 is not on the causal pathway. 
In contrast, if IM-12 is not a necessary product of IM-13 or their association is not 
strong (e.g. there is considerable variability between individuals), IM-12 may be only 
weakly correlated with vaccine efficacy (VE).
EXAMPLE
It is widely accepted that BCG-induced protection against tuberculosis is via cell-mediated immune 
mechanisms (corresponding to IM-11 or IM-13 in Figures 6 and 7). There has been some interest in whether 
the presence or size of a BCG vaccine-induced scar might be related to the degree of vaccine-induced 
protection against pulmonary tuberculosis (7). In this context, it is unclear whether the scar reflects only a 
local response to the vaccine (analogous to IM-10 in Figure 6), or whether the scar is a collateral product 
of the protective immune response induced by the vaccine (i.e. analogous to IM-12 in Figure 7). 
The complete chains of causality and interrelationships between vaccination, 
immune responses, protection and clinical endpoints are likely to be considerably more 
complex than the scenarios described above for most vaccines. New models continue to 
be developed. For example, a recent study by Kester et al. analysed combined humoral 
and cellular immune readouts to assess the independent and combined effects of T cell 
and antibody responses on protection against malaria (8). Drawing up causal diagrams 
allows a summary of the current stage of knowledge about these interrelationships and 
informs how the data may be analysed, using causal modelling or other techniques 
(9).
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A variety of approaches have been used to identify, confirm and evaluate immunological 
markers as indicators of vaccine-induced protection. It is important to appreciate the 
logical arguments inherent in these designs, as they determine the nature and strength 
of the evidence. They are reviewed briefly below, with examples of their use. 
To facilitate this discussion, a very simple diagram (Figure 8) depicts a situation in 
which a vaccine’s effect is mediated entirely through a single substitute endpoint 
(immune marker). The effect of the vaccine on the clinical endpoint is represented by 
the dotted arrow, and the associations between the vaccine and substitute endpoint and 
between the substitute endpoint and clinical endpoint are represented by solid arrows 
[a] and [b], respectively. 
Figure 8. Simplest possible relationship between vaccine,  
substitute endpoint and clinical endpoint
Vaccine
Substitute endpoint
(immune marker)
Protection against 
clinical endpoint
3.1 Trials and other experimental designs 
Many investigators have allocated vaccines or immune globulins to humans or animals, 
and followed them up to assess either the immune response to vaccination and/or 
incidence of the clinical disease, compared to a control group who were not given 
the vaccine or globulins. Such designs allow the tightest possible control of potential 
confounding factors. 
There are several studies in which results derived in animal experiments have been 
extrapolated to humans (10–11). However, results from animal models are not always 
directly applicable to humans. For instance, serum IgA is actively transported into bile 
in the mouse model of rotavirus infection, but not in humans; thus protection against 
rotavirus in mice may not reflect the mechanism in humans (12).
3.1.1 Randomized controlled trials with clinical endpoints
Randomized controlled trials (RCT) provide the ideal context to assess all elements of 
Figure 8: vaccine efficacy, the association between vaccination and immune markers (step 
a) and the association between markers, protection and clinical endpoints (step b). 
3. Study designs to evaluate 
vaccine-induced substitute 
endpoints
Correlates of vaccine-induced protection: methods and implications10
EXAMPLES
Santosham et al. (1991) carried out an RCT among infants to measure the efficacy of 2 doses of a 
Haemophilus influenzae type b (Hib) polysaccharide-OMP conjugate vaccine. Levels of serum 
antibody to Hib capsular polysaccharide were measured in all participants (2588 vaccinees and 2602 
non-vaccinees) before the first dose of vaccine, at 2 months after the first dose, and at 2 and 8 months 
after the second dose. Infants were followed up for clinical disease with microbiological confirmation of 
H. influenzae infection. The authors analysed the associations between vaccination and clinical infection, 
observing 95% (95% CI: 72–99%) protection (the dotted arrow in Figure 8). As an antibody concentration 
of 0.15 µg/ml was thought to be protective (13), they noted that 45% infants had antibody concentrations 
above this prior to vaccination, rising to 90% at 2 months after the first and second doses, declining to 
24% at 8 months after the second dose (reflecting step a in Figure 8). The only case among vaccinated 
children occurred at 15 months in a child whose antibody concentration was 1.49 µg/ml at 2 months after 
the second dose, but had declined to 0.14 µg/ml at 1 year of age, 3 months prior to illness (step b).
Participants in the Medical Research Council trial of BCG efficacy against tuberculosis (initiated in 1950) 
were negative to 100 IU tuberculin as an entry criterion to the trial (13 598 received BCG, 5817 received 
M. microti vaccine and 12 867 controls received nothing). All were skin tested 1 year after entry into the 
trial, giving data on ‘step a’, and followed up over the subsequent 20 years. Although BCG vaccination 
was shown to impart almost 80% protection against tuberculosis for the first 10 years after vaccination, 
this protection was not related to the level of vaccine-induced tuberculin reactivity (step b of Figure 8). 
The authors of the main report thus concluded “…with highly effective tuberculosis vaccines, the degree 
of protection conferred on the individual is independent of the tuberculin sensitivity induced by the 
vaccination” (14).
Saaka et al. (15) reported on a sub-study within a major trial of a 9-valent pneumococcal conjugate vaccine 
in the Gambia. The trial showed that the vaccine provided 77% protection against vaccine serotype-specific 
invasive pneumococcal disease (IPD), i.e. the dotted line in Figure 8. Blood was collected from 212 of 
17 437 children enrolled and serum antibody levels compared between those allocated vaccine and those 
receiving the placebo (Figure 9). The geometric mean titres and proportion of infants with antibody levels 
above 0.2, 0.35 and 1.0 µg/ml were appreciably higher in the vaccine group compared to the placebo 
group (step a in Figure 8). Using the methods described here in Section 4.2.2, they estimated a geometric 
mean protective antibody titre for all 9 serotypes combined to be 2.3 µg/ml (95% CI: 1.0–5.0) (step b).
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Figure 9. Reverse cumulative distribution of antibody titres to each  
vaccine serotype in children receiving placebo or three doses of  
9-valent pneumococcal conjugate vaccine 
   A, placebo; B, pneumococcal conjugate vaccine
   Source: Reprinted from Saaka et al. (15) with permission from Elsevier.
3.1.2 Immunogenicity studies
These are exemplified by phase II vaccine trials in which individuals receive (preferably 
at random) a vaccine of interest or a placebo or older formulation of the vaccine, 
and their immune responses compared. Immunogenicity studies measure step a in 
Figure 8 and are typically carried out either prior to a full clinical efficacy trial or as 
part of a “bridging” exercise to compare the immunogenicity of a new batch or product 
with that of a known efficacious product. 
Correlates of vaccine-induced protection: methods and implications12
EXAMPLES
Meningococcal C conjugate vaccine was licensed in the United Kingdom as a result of phase II 
immunogenicity studies. These compared serum bactericidal assay titres induced by the new vaccine to 
those induced by a licensed serogroup C polysaccharide vaccine, which demonstrated direct evidence of 
efficacy and accepted correlates of protection (16). The studies used rabbit complement (rSBA) with the 
“gold standard” criterion for protection based on serum bactericidal assay titres using human complement 
(hSBA) (17). Classic studies by Goldschneider et al. had shown that hSBA titres of ≥4 indicate protection 
and that some individuals with titres below 4 are also protected (18). Paired sample studies using both 
rSBA and hSBA showed that 85% of individuals with rSBA <8 had hSBA <4, and 93% of those with rSBA 
titres ≥128 had hSBA titres ≥4. However, for those with rSBA titres between 8 and 128, protection could 
be assumed if the rSBA titres rose fourfold as a consequence of vaccination. These studies involved the 
measurement of each step in Figure 8. 
Edelman et al. vaccinated 116 volunteers with an alum-adsorbed purified botulinum F toxoid 
by one of three different schedules − intramuscular and subcutaneous administration, and 
boosters − and followed them up over two years. Response was measured as mouse anti-
toxin titres. As 100% of guinea pigs with titre greater than 0.04 IU/ml, and 50–100% of guinea 
pigs with titres over 0.01 IU/ml, survived a challenge with 105 LD50 of type F toxin, a titre of 
0.02 IU/ml was considered protective in humans. Using this criterion, it was estimated that the new 
vaccine left 7–16% of volunteers “unprotected” after eight weeks, and that 33–42% were not protected 
after one year (10).
A WHO leprosy vaccine including BCG and killed leprosy bacilli was first evaluated immunologically 
in Norwegian nurses and later in Malawi. A dose-response relationship between the concentration 
of killed leprosy bacilli in the vaccine and induced skin test reactivity to soluble antigens extracted 
from M. leprae (MLSA) was used to select the vaccine dose for subsequent trials (step a in 
Figure 8) (19). Both BCG alone and BCG + killed M. leprae were found to impart approximately 
50% protection against leprosy in Malawi (dotted line in Figure 8), and skin test sensitivity to 
M. leprae antigens was found to correlate negatively with leprosy incidence in a general population in 
Malawi. However, there was no direct evaluation of whether vaccine-induced sensitivity to MLSA was 
associated with protection (step b in Figure 8) (20–21).
3.1.3 Passive immunization studies 
Susceptible animals or human volunteers may be administered specific immune globulins 
and then followed up to evaluate the rate of natural infection as a function of antibody 
titre, effectively measuring step b in Figure 8. An important issue in these studies is 
whether the (passive) antibody titre required to provide protection may be higher than 
the antibody level associated with protection following natural infection, because it is 
not “supported” by other elements of the natural immune response. 
EXAMPLE
Santosham et al. and O’Reilly et al. (22–23, respectively) administered Hib immune globulin 
prophylaxis to patients with agammaglobulinaemia and to newborn infants, respectively. 
Their results indicated that a serum antibody level of 0.15 µg/mL protected against invasive Hib disease 
in the short term, and that a level of 1 µg/mL was protective in the long term. 
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3.1.4 Challenge studies
Animals or human volunteers with known natural or vaccine-derived levels of immune 
marker may be challenged with different doses of a pathogen, and their responses 
related to their pre-challenge immune status. Again, these studies measure step b of 
Figure 8.
EXAMPLES
0.01 IU/ml of tetanus anti-toxin, measured in a neutralization assay in mice or guinea pigs, has been 
considered a minimum level for protection against tetanus. This level was based originally upon experiments 
with guinea pigs challenged with live C. tetani spores and on experience with horses given homologous 
antisera after acute injury carrying high tetanus risk. Several reports indicate that the 0.01 IU/ml level may 
not always be sufficient in humans with deep or necrotic wounds in which spores may be sequestered 
from circulating anti-toxin (11). 
Tacket et al. (24) randomly allocated 85 volunteers to vaccination with an attenuated live cholera 
vaccine or a placebo, and measured levels of serum vibriocidal antibodies and serum IgG anti-
cholera toxin antibodies after 10 days. A total of 51 volunteers (28 vaccinated and 23 placebo) 
had their immune response reassessed after three months and were subsequently challenged 
with an oral dose of 105 CFU of virulent Vibrio cholera 01. Among the vaccinated individuals, 
no association was found between 10-day or pre-challenge vibriocidal antibody titre and protection 
against cholera diarrhoea. 
3.2 Observational studies 
This term is used in its conventional epidemiological sense, implying studies involving 
only passive observation of groups or populations, with no controlled intervention. 
3.2.1 Cohort studies
In cohort studies, individuals may be classified on the basis of their vaccination status 
and followed up to measure the immune response as the outcome of interest (step a of 
Figure 8). Alternatively, subjects may be classified by their immune response status and 
followed up to compare the occurrence of the clinical endpoint (step b of Figure 8). 
EXAMPLES
Chen et al. (5) took advantage of an outbreak of measles among university students which took place 
shortly after a blood drive. Measles antibody titres in 90 stored samples of the donated bloods were 
measured by plaque reduction neutralization (PRN) and enzyme immunoassay (EIA). Most of the students 
had received measles vaccine as children. Eight out of 9 individuals with pre-exposure PRN titres of <120 
contracted clinical measles according to the Centers for Disease Control and Prevention (CDC) case 
definition, compared to none of the 71 individuals with PRN titres >120. Although individuals with PRN 
titres >120 did not contract classical measles, 26 (70%) of 37 with pre-exposure titres <1052 reported 
at least one symptom, compared to 11 (35%) of 35 individuals with titres >1052. These data have been 
cited widely to support a PRN of 120 as a correlate of protection against clinical measles.
Jack et al. (25) followed children vaccinated with the plasma-derived hepatitis B vaccine in the Gambia, 
and correlated their levels of the antibody with subsequent incidence of hepatitis B surface antigen 
carriage. The results suggested that reaching a peak antibody level of >10 IU/L in the year following 
vaccination was associated with protection against hepatitis B persistent infection over the subsequent 
seven years (Figure 8, step b).
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3.2.2 Natural history studies
Analysis of the immune response after recovery from an infectious disease may give an 
indication of protective components of acquired immunity, in particular for diseases 
associated with long-lasting natural protective immunity such as measles, varicella and 
mumps. 
EXAMPLE
Ndumbe et al. (26) measured varicella-zoster virus (VZV)-specific antibody levels and lymphocyte 
stimulation responses to VZV antigen in 23 individuals who had experienced chickenpox either 
6−8 weeks (n=10) or more than 5 years (n=13) previously. The geometric mean antibody titres 
(measured using an immunofluorescence test) among the 10 individuals with recent chickenpox 
was 158 (SD: 9.2, range <8−2048) compared with a mean titre of 41.8 (SD: 2.9, range <8−128) 
among those with less recent chickenpox. For the lymphocyte transformation tests (LTT), 
the stimulation indices ranged from 4.3–14.1 for those with recent infection, and from 6.1–24.2 for those 
with earlier infection. Given that second episodes of chickenpox are rare, all of these antibody and LTT 
levels may be interpreted as sufficient for protection against chickenpox disease. As declining cell-mediated 
immunity to VZV is probably associated with clinical zoster, and all these subjects were clinically well, the 
lower levels may also be interpreted as correlates of protection against zooster.
3.2.3 Maternal–newborn studies
The low incidence of vaccine-preventable diseases in neonates provides evidence for 
the protective role of maternal antibodies (27−28). Measurement of these antibodies 
and their rate of decline can give information on step b in Figure 8. As with the passive 
immunization studies mentioned in Section 3.1.3, it may be that the level of passively 
acquired maternal antibody required for protection is higher than the level needed 
if antibodies are actively acquired, as maternal antibodies lack the contribution or 
“support” of elements of the immune system that are not transferred across the placenta, 
e.g. those dependent upon lymphocytes. 
EXAMPLES
Cord bloods and repeat samples every two months were collected from 1087 infants born in Nairobi, 
Kenya and tested for HI measles titres. The infants were allocated to receive measles vaccine at 5, 6, 7, 
8, 9 or 12 months of age. This allowed detailed monitoring of the loss of maternal antibody and revealed 
that only 1 of 13 children with a pre-vaccination titre of 1:6, and neither of 2 children with a pre-vaccination 
titre of 1:12 seroconverted as a result of measles vaccination (29). This provides a correlate of “protection” 
against measles vaccine virus infection.
Glass et al. (30) followed 93 breastfeeding mother–child pairs in order to investigate whether IgA antibodies 
against cholera toxin and lipopolysaccharide protect against colonization with Vibrio cholerae 01 and 
disease. Mothers without diarrhoea were recruited from households with cholera patients. IgA antibody 
concentrations were measured in breast milk, and infants were followed for the occurrence of colonization 
or disease. The researchers found no difference in the mother’s breast-milk antibody concentration 
between colonized and non-colonized children, but the antibody concentration in breast milk was higher 
in colonized children who did not develop diarrhoea compared to those who did. This suggests that these 
IgA antibodies may protect against disease but not colonization. 
15WHO/IVB/13.01
3.2.4 Case–control studies
The case–control approach has been used to compare levels of immune markers prior to 
disease among individuals who did or did not develop the clinical outcome of interest 
(step b of Figure 8). The blood samples must have been collected prior to disease onset, 
and preferably prior to the exposure to infection. This often implies the sampling and 
testing of stored blood samples. 
EXAMPLE
During an RCT of acellular pertussis vaccine in Sweden (31), serum samples were collected from children 
21–77 days after vaccination and stored. These samples were later used in a nested case–control study 
of 126 children exposed to pertussis in their household. Children who developed pertussis (cases) were 
found to have had lower pertussis toxin (PT) IgG antibody levels in their stored samples than children 
who did not develop pertussis (controls): median concentrations among cases were respectively 
79 U/ml for those with severe disease and 156 U/ml for those with mild disease, compared to a median 
concentration of 246 U/ml among controls (who contracted no disease). IgG to pertussis toxin thus 
correlates with protection in this context – but a precise level to use as a correlate cannot be specified. 
The combined effects of  PT and other pertussis antibodies in predicting protection against pertussis 
disease are discussed in Section 4.1.2. 
3.2.5  Ecological studies
In ecological studies, associations are drawn between vaccination status, the substitute 
endpoint (e.g. antibody titre) and the clinical endpoint only at the population level. 
It is therefore not possible to draw conclusions about the associations of interest at 
the individual level.
EXAMPLE
The efficacy of BCG against pulmonary tuberculosis has been shown to be lower in populations from 
Malawi than those from the United Kingdom. A series of studies compared data from the two countries to 
understand this difference, and to investigate potential substitute endpoints for protection (32–35). It was 
shown that pre-vaccination IFN-y response to PPD-Mtb (used as an indicator of T cell immune response) 
was well correlated to delayed-type hypersensitivity to M. tuberculosis antigens in both populations 
(32-33). It was also found that unvaccinated adolescents in Malawi had higher IFN-y responses than 
unvaccinated British individuals. Because of this difference in background level prior to vaccination, the 
increase in immune response after vaccination with BCG is higher in the United Kingdom than in Malawi 
(34). These studies did not demonstrate that any particular IFN-y response was a correlate of vaccine-
induced protection against tuberculosis, but that the vaccine-associated change in IFN-y correlated with 
the vaccine-associated protection observed in the two populations.
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Many of the examples above refer to correlations between one or more immune 
markers and degree protection. But statistical correlations are not helpful unless 
they are strong, and ideally reveal some clear criterion indicating protection. 
Several authors have addressed the statistical issues involved in the evaluation of interventions 
through substitute endpoints. Much of this literature is drawn from non-vaccine fields, 
such as cardiovascular disease or cancer risks and treatment effects (36). In the context 
of vaccines, several sorts of questions have been discussed:
How to make the step from demonstration of i) correlation between a substitute 
endpoint and protection, to identification of a useful correlate? 
How to distinguish between a ii) correlate and a surrogate of protection (using the 
causal pathway criterion)?
If an immune marker is a valid substitute endpoint in individuals, what is the iii) 
relationship between the distribution of vaccine-induced titre(s) of the marker 
in populations and VE?
4.1 General methods for validating immunological markers as substitute 
endpoints for clinical protection
The demonstration that a vaccine induces an apparently “specific” immune response 
(Figure 8 step a) is not proof that the vaccine is protective. Similarly, the fact that 
an immune response is statistically associated with the risk of the clinical endpoint 
(Figure 8 step b) does not mean that it is responsible for the protection, or that it can 
predict the protective effect of the vaccine. Further criteria are needed.
4.1.1 The Prentice criteria 
A key concept was introduced by Prentice in 1989 (3) in the context of a hypothesis-
testing approach to the validation of substitute endpoints using RCT data. His four 
criteria for validation of a surrogate endpoint can be adapted for vaccine trials as 
follows:
Protection against the clinical endpoint is significantly related to having received i) 
the vaccine (the dotted line in Figure 8);
The substitute endpoint is significantly related to the vaccination status ii) 
(step a in Figure 8);
The substitute endpoint is significantly related to protection against the clinical iii) 
endpoint (step b in Figure 8);
4. Statistical methods for  
evaluation of substitute  
endpoints
Correlates of vaccine-induced protection: methods and implications18
The full effect of the vaccine on the frequency of the clinical endpoint is explained iv) 
by the substitute endpoint, as it lies on the sole causal pathway.
If the full effect of the vaccine is mediated via the immune marker (criterion iv), 
the incidence of the clinical endpoint should be the same among vaccinated and 
unvaccinated individuals at any particular titre of the immune marker, and the 
protective effect of the vaccine should disappear after adjusting for immune marker titre 
(e.g. in an individual level regression model).
EXAMPLE 
Qin et al. (4) used data from a trial of a trivalent influenza vaccine carried out in 1943 and reported by 
Salk et al. (37) to illustrate the validation of influenza-specific antibody titre as a surrogate of protection for 
hospitalization with influenza (the clinical endpoint), using the Prentice criteria. VE of 73% was reported 
against hospitalization with influenza Weiss strain A (criterion i). Antibody titres to Weiss strain A were 
higher in vaccinated compared to unvaccinated individuals (criterion ii). The antibody titres were inversely 
associated with hospitalization for influenza (criterion iii). The risk of hospitalization was almost identical 
in vaccinated and unvaccinated individuals after adjusting for antibody titre (criterion iv). 
The Prentice criteria were originally proposed for the statistical validation of substitute 
endpoints in the context of randomized controlled clinical trials. Schatzkin et al. (38-39) 
pointed out that this method could also be applied to observational studies. 
The criteria are based on statistical associations, and criticisms of the criteria include 
the following.
As Prentice acknowledged, the requirement that the substitute endpoint explains •	
all the effect of the intervention (e.g. vaccination) on the clinical endpoint is 
restrictive. For many vaccines, it is unlikely that a single causal pathway leads 
from vaccination to clinical protection.
Validation depends on showing that the incidence of the clinical endpoint in •	
vaccinated and unvaccinated individuals is the same within each stratum of 
immune marker titre. Thus the regression model should include all subject 
characteristics that may predictboth the immune response endpoint and 
the disease/infection endpoint (40-41). The immune marker is measured 
after randomization and is itself affected by the intervention (vaccination). 
Thus the subgroups of individuals in each immune marker category are selected 
after randomization and the approach is susceptible to post-randomization 
selection bias insofar as the precise titre is influenced by factors other than the 
vaccine, such as age or host genetics (42). For example, a particular vaccine may 
be ineffective in young children (it does not induce a strong antibody response) 
but highly effective among older children (inducing high antibody titres), 
and younger children in a trial population may be at higher risk of disease than 
older children because they mix more and have higher intensity of exposure. 
In this scenario, vaccinated individuals with low antibody titres will include a 
higher proportion of young children than unvaccinated individuals with the same 
low titres, and this will result in different probabilities of disease in vaccinated 
and unvaccinated children due to the different age profile.
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There needs to be sufficient variability in the immune response among the •	
unvaccinated individuals to allow comparison. For example, some of the 
unvaccinated need to have acquired the immune marker from previous exposure 
to the pathogen or related antigens. Validation of a surrogate using the Prentice 
method is not possible if the immune response being assessed occurs only after 
vaccination, e.g. if the response is not induced by natural exposure to the same 
or related antigens. (43) 
The Prentice criteria cannot be used to “prove” that the surrogate explains •	
all the effect of a vaccine. This is because, in the adjusted model, it can never 
be shown that the relative risk associated with vaccination becomes exactly one 
(i.e. has no effect) after adjustment for precise antibody titre, only that the data 
are compatible with such a result.
4.1.2 Proportion of treatment effect
Adaptations have been made to the Prentice criteria in order to evaluate immune 
markers as substitute endpoints when there is more than one causal pathway between 
vaccination and the clinical endpoint of interest. In this circumstance, the question 
arises as to the proportion of the observed protection that can be explained by one or 
more of the pathways or markers. This general problem in epidemiology is sometimes 
described in terms of estimating the proportion of a treatment effect (PTE) explained 
by a marker (44). At its simplest, the PTE can be described as (β-βa)/β, in which β is 
the unadjusted effect of vaccination on the clinical endpoint and βa is the effect adjusted 
for the immune marker (45). 
EXAMPLE
Storsaeter et al. (46) used the combined effect of pertussis antibodies in a logistic regression model to 
predict the risk of pertussis disease. They showed that IgG antibodies against three pertussis antigens 
(pertussis toxin, fimbriae and pertactin) were correlated with protection against clinical pertussis following 
household exposure (criterion iii of Prentice). Kohberger et al. (47) validated Storsaeter’s model using the 
Prentice criteria, demonstrating that protection against pertussis was significantly related to vaccination 
(criterion i) and that vaccination was significantly related to pertussis antibody status (criterion ii). 
After investigating criterion iv of Prentice, they concluded that the combined antibody response explained 
93% (95% CI: 51–100%) of the effect of the vaccine. 
Concerns raised about the PTE method include the fact that it may not be a proportion 
(i.e. it may come out to less than 0 or more than 1) under certain circumstances (45). 
Participants at a 2001 National Institutes of Health workshop (reported by De Gruttola 
et al., 48) cautioned against the use of the PTE approach to assess surrogate endpoints in 
clinical trials, citing studies that demonstrated the difficulty of interpreting the PTE. 
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4.1.3 The Qin framework 
Qin et al. (4) proposed a hierarchical framework to assess the validity of immunological 
markers as substitute endpoints, which distinguishes three different levels of association, 
termed as follows:
Correlate of risk;i) 
Level 1 “specific” surrogate of protection, divided into “statistical” and ii) 
“principal” surrogates;
Level 2 “general” surrogate of protection. iii) 
Statistical methods for applying the framework were reported by Gilbert et al. (40). As 
noted in Annex 1, Qin et al. define a correlate of risk (CoR) as an immune response 
that is associated with protection against a clinical outcome, whereas a surrogate of 
protection (SoP) is a CoR that predicts accurately the level of VE. Their definition of a 
correlate raises little difficulty, but their perspective on surrogates is more challenging 
and differs from the causality criteria suggested by other authors and outlined in Section 
1.1. The division into level 1 and level 2 reflects whether the data relate to single or 
multiple populations, respectively. 
The level 1 (specific) SoP is defined as “an immunological measurement that is a CoR 
within a defined population of vaccinees and is predictive of [vaccine efficacy] VE in the 
same setting as the trial”. These surrogates are in turn subdivided into two categories 
(“statistical” and “principal”) according to the logic of their validation: 
A level 1 “statistical” SoP is an endpoint that satisfies the Prentice criteria.•	
A level 1 “principal” SoP is defined using a particular framework of •	
causal inference, based on earlier methodological work such as that by 
Frangakis et al. (49), Rubin (50), and Follmann (51). This framework aims to 
address post-randomization selection bias found with the validation using the 
Prentice criteria, by estimating what the vaccine responses would have been 
had the non-vaccinated group been vaccinated. Follmann (51) and Qin et al. 
(4) suggest two methods to estimate these responses: (a) including a baseline 
irrelevant predictor (defined as a variable that correlates with measured levels 
of the immune marker but is not itself predictive of disease given the immune 
response), or (b) vaccinating a subset of uninfected controls at the end of the 
trial to see what their responses are (although these controls are themselves a 
selected group in that they did not develop disease during the trial). The logic of 
this approach is explained in greater depth in the paper by Gilbert et al (40) and 
in the commentary by Gilbert et al (41).
The level 2 “general” SoP is a surrogate that has been shown to predict VE across 
a range of different populations and settings, and can thus be used to assess VE in 
untested populations. A meta-analytical approach has been proposed to evaluate level 
2 surrogates, using data collected from multiple trials. For each trial, the observed VE 
is plotted against measured differences in the immune response between vaccinated 
and unvaccinated individuals (Figure 10). The resulting relationship can be used to 
estimate VE in a new setting, based on the immune responses measured in that setting. 
This approach is data intensive (each study is a single data point) and extrapolation 
may not always be appropriate. 
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Figure 10. Level 2 surrogate of protection
 Source: adapted from Qin et al. (4).
4.2 Methods for relating vaccine efficacy to measured levels of vaccine-
induced immune markers 
The approach used to validate a level 2 SoP in Qin’s framework is one way to analyse 
the relationship between a substitute immune marker (for example, the mean difference 
in titres between vaccinees and non-vaccinees) and clinical protection by a vaccine. 
Other methods to do this can be divided into two main categories: threshold and 
continuous methods (Sections 4.2.2 and 4.2.3). 
This Section begins by considering the distributions of immune markers in populations: 
their relationship to vaccination and their implications for protection. How these 
distributions can be harnessed to estimate VE is then discussed.
The methods discussed in this Section implicitly assume that the Prentice criteria 
are fullfilled, in particular that the relationship between the immune marker and the 
protection is the same in the placebo and the vaccinated groups. These methods are 
therefore susceptible to the criticisms associated with the Prentice criteria discussed in 
Section 4.1.1; for example the requirement for some variability in the immune response 
among the unvaccinated (placebo) groups. As highlighted in Section 4.1.3. Qin et al. 
(4) propose alternative methods within their framework that can be used to evaluate a 
potential immune marker in situations where there is no variability in the unvaccinated 
group.
4.2.1 Distribution of antibody titres and their implications 
If a vaccine influences an immune marker, e.g. antibody titres to some particular antigen, 
this may be manifested in different population patterns. In some circumstances the 
distribution in non-vaccinees may be “low and narrow” – i.e. they may have very 
little response in assays for antibody to the antigen in question, and the distribution 
in the vaccinees may be clearly distinct, with little or no overlap between them 
(Figure 11A). In other circumstances there may be little antibody in the non-vaccinees, 
but the distribution in vaccinees may be bimodal, indicating that the vaccine “took in” 
(i.e. induced an immune response in) a proportion of vaccine recipients, but failed to 
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“take in” the remainder (Figure 11B). In a third circumstance the non-vaccinees may 
have a broad range of antibody titres, in which case the distribution of antibody response 
in vaccinees may end up with a greater or lesser overlap with that in the non-vaccinees 
(Figure 11C). These represent extremes of a spectrum of patterns which may occur 
with different vaccines and different immunological measures.
Figure 11.Three patterns of distribution of antibody titres  
in vaccinees and non-vaccinees 
A. B.
C.
 Solid lines, vacinees; dotted lines, non-vacinees.
Whatever the immune marker distributions among vaccinees and non-vaccinees, 
it is useful to consider them in relationship to protection, as illustrated in Figure 12. 
Here, a distribution of antibody titres is represented by the (lower line) frequency 
distribution, in this context ignoring whether or not individuals have been vaccinated 
or have a history of natural exposure. The upper cumulative frequency line represents 
the relationship between the immune marker and “protection”. Assuming the Prentice 
criteria holds, individuals with less than a 1.5 log titre have little or no protection, 
whereas those with more than 3.0 logs have 100% protection. 
In Figure 12, a log antibody titre of 2.3 is associated with 70% clinical protection – 
i.e. it reduces the risk of disease by 70% compared to individuals with less than 1.0 log 
antibody titre. What determines the variation in such antibody distributions and why 
a given titre may provide only 70% protection is discussed below.
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Figure 12. Relationship between clinical protection and log antibody  
titre, and distribution of log antibody titres
distribution of 
antibody titres
probability of 
protection
 The shaded area represents the proportion of individuals with antibody titres above a cut off of 2.3, 
who have at least a 70% probability of protection against the clinical endpoint.
 Source: adapted from Nauta et al. (52).
Nauta et al. (52), using influenza vaccination for illustration, showed that the relationship 
between antibody titres and clinical protection in a population depends not only on 
the mean but also on the standard deviation of the log-transformed antibody titres 
in that population. As a consequence, both parameters need to be considered when 
generalizing findings from a single population. 
The ideas from Figures 11 and 12 can be used to evaluate vaccine efficacy. 
4.2.2 Threshold methods 
Threshold methods assume a step function: that there is a simple threshold level of 
the immune marker above which individuals are fully protected against the clinical 
endpoint and below which they remain fully susceptible (Figure 13). Consistent with 
the Prentice criteria, they also assume that this threshold is similar in vaccinated and 
unvaccinated individuals. 
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Figure 13. Hypothetical relationship between antibody titre  
and clinical protection with a simplifed ‘step function’
 Solid line, relation between antibody titre and clinical protection; dotted line, simplified step function. 
Source: adapted from Siber et al. (53). 
The simplest way to estimate such a threshold is to relate pre-exposure immune 
marker titres to disease incidence in a cohort study and to adopt the titre above which 
no individual develops the clinical endpoint as the protective threshold. Thresholds 
derived using these methods are sometimes referred to as individual-based correlates of 
protection (54). An example of this is the study of Chen et al. (5) (Section 3.2.1) in which 
the surrogate of protection against measles, a PRN titre >120 mIU/mL, was derived 
by finding that nobody with an antibody titre above that threshold developed typical 
clinical measles during the outbreak studied. Other published examples of individual-
based immunological markers of protection relate to diphtheria and rubella (55−56). 
A second method uses the proportion of vaccinated and unvaccinated individuals below 
specified thresholds to estimate VE. The inference from correlate of protection to VE 
is based upon the traditional equation for observed clinical VE:

VE, vaccine efficacy; CE, clinical efficacy; 
Given that disease incidence should be a direct function of the proportion susceptible 
(assuming equal exposure), and assuming that a simple step function in the immune 
marker separates susceptibility and immunity, this translates directly into an equation 
for the immune marker-derived VE, here called VEIM (53):

VE, vaccine efficacy; IM, immune marker
The VEIM can be derived by measuring immune marker titres in vaccinated and 
unvaccinated individuals and presenting them graphically, either as distributions of 
log-transformed titres for each group (as in Figure 14A) or as reverse cumulative 
distributions (as in Figure 14B). Such figures allow inferences from observed VECE 
to estimated immune marker thresholds for protection, or vice versa, from known 
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protective thresholds to estimated clinical VE, based upon equation 2. For example, 
if VECE has been estimated clinically, VEIM can be estimated from the graph for each 
possible immune marker threshold using equation 2, to identify the threshold for which 
VEIM equals VECE.
Figure 14. Graphic display of distributions of antibody titres in vaccinated and 
unvaccinated individuals, allowing inference from observed vaccine efficacy to 
protective threshold
Observed VECE=75%
Estimated VEIM = 1 - [16.8/67.2] = 75%
Unvaccinated Vaccinated
A
Proportion with ab titres<1.7:
– vaccinated (1-0.832)=0.168
– unvaccinated (1-0.328)=0.672
B
Unvaccinated Vaccinated
A) Distributions of log antibody titres, adapted from Dunning et al. (57); VE is estimated from the 
graph for each possible threshold using equation 2. In this example, the estimated VE is equal 
to the observed VE (75%) if an antibody threshold value of 1.7 is assumed to be protective 
(67.2% of unvaccinated and 16.8% of vaccinated individuals have an antibody titre below this 
threshold). 
B) Reverse cumulative distribution of antibody titres in vaccinated and unvaccinated individuals, 
showing the same calculation.
Correlates of vaccine-induced protection: methods and implications26
EXAMPLES
Siber et al. (53) report the statistical methods used by a WHO working group to derive the concentration 
of anti-pneumococcal capsular polysaccharide antibodies to pneumococcal conjugate vaccine (PCV) that 
predicts protection against IPD in immunized infants. They pooled results from three RCTs of pneumococcal 
VE − two trials in the USA (one in Californian infants and the other in American Indian infants) using 
the USA schedule of 2, 4, 6, and 12 months with 7-valent pneumococcal vaccine, and one in Soweto, 
South Africa, using the EPI schedule of 6, 10 and 14 weeks with 9-valent pneumococcal vaccine. 
The South African trial data were restricted to efficacy against the seven serotypes present in the vaccine 
used in US trials. The protective titre was derived graphically from the reverse cumulative distribution of 
antibody concentrations in vaccinated and unvaccinated infants, as in Figure 14B above. A concentration 
of IgG anticapsular polysaccharide antibodies of ≥0.35 µg/ml measured by ELISA one month after primary 
immunization was recommended as the protective threshold and as the basis for licensing PCV. 
Andrews et al. (58) used the threshold method to re-evaluate and validate titres of serum bactericidal 
antibody (SBA) as a substitute endpoint for meningococcal C conjugate vaccine-induced protection after 
the SBA assay was changed to use rabbit rather than human complement (as mentioned in Section 3.1.2). 
Post-licensure surveillance data were used to estimate observed vaccine effectiveness (VE), and this 
was compared with predicted VE calculated for a range of different assay cut-offs, using the step-function 
assumption and equation 2 above. Among toddlers, an rSBA cut-off of 8 at one month post-vaccination 
gave the closest estimated VE to that observed in the first year after vaccination (Figure 15). 
Figure 15. Predicted vaccine efficacy based on the proportions of vaccinated  
and unvaccinated toddlers with rSBA titres below a range of cut-offs,  
measured one month after vaccination with meningococcal C conjugate  
vaccine (see equation 2)
 Source: reprinted from Andrews et al. (58) with permission from Elsevier.
4.2.3 Continuous method 
It is also possible to relate immune marker titres to disease risk and hence to VE without 
assuming a threshold titre associated with protection. Siber (54) describes the calculation 
of antibody titre-specific rates of disease by dividing the number of individuals with 
disease who had a specific pre-exposure titre by the number of individuals in the entire 
study population with that titre, and used this to infer the overall proportion protected 
against disease. Other researchers have fitted regression models to antibody titres in 
vaccinees and non-vaccinees in order to describe a statistical association between pre-
exposure antibody titres and disease incidence and thus to estimate VE.
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EXAMPLES
Chan et al. (43) examined a range of different regression models to describe the association between 
antibody titres after varicella vaccination and subsequent disease incidence in order to infer clinical 
protection. They showed that VE predicted by the models was similar to that observed from seven-year 
follow-up data from a varicella VE trial (97.4% compared to 97.0%, respectively).
As outlined in Section 4.1.2, Storsaeter et al. developed a logistic regression model to quantify the 
relationship between antibodies to three different pertussis antigens and vaccine-derived protection against 
clinical pertussis after household exposure, in a vaccine trial in Sweden. This model was subsequently 
validated by Kohberger et al. (46−47) using Prentice criteria and meta-analysis. The VE predicted from 
the model was reasonably consistent with the results from a second vaccine trial in Sweden. 
Dunning (59) highlighted the inability of existing models to capture appropriately the relationship between 
antibody titre and clinical protection in individuals with low antibody titres, in whom the risk of disease could 
be highly influenced by the probability of exposure to an infectious contact, the prevalence of infection or 
other factors independent of the antibody titre. He proposed a new (scaled logit) model which includes 
a continuous relationship between levels of the immune marker and protection in which exposure is 
modelled explicitly. This approach has been used subsequently to model the relationship between CMI 
responses to influenza vaccination in children and protection against culture-confirmed clinical infection 
with wild-type influenza virus (60).
4.2.4 Summary
There are various ways to relate immune markers to VE. As described in this Section, 
some methods use antibody titres as continuous variables to predict VE, whereas other 
methods transform this information into a dichotomous variable − a threshold level of 
an immune marker above which subjects are assumed to be protected and below which 
they are not. Both approaches have their limitations. As discussed in section 4.1.1, most 
methods presented here stratify on the immune response, and are thus susceptible to 
post-randomisation bias if using data from a randomised trial. It is therefore necessary 
whenever possible to adjust for factors other than the vaccine that could affect the 
risk of infection/disease. The relationship between immune marker titres and clinical 
protection is further discussed in Section 6. 
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5.1 Endpoint definition
It is important to specify explicitly the clinical endpoint against which the vaccine 
is expected to protect, since the relationship may vary depending on this outcome. 
Endpoints of interest include infection, illness, death, carriage, infectiousness and 
(for diseases such as malaria that are almost universal in certain settings) time to first 
endpoint or total number of disease episodes. Protection against clinical endpoints may 
require not just different quantities of a specific immune marker but involve different 
markers.
EXAMPLES
Studies of smallpox vaccine suggest that high antibody titres protect against infection, but that both 
antibody and T cell responses are needed to protect against severe disease (61).
For Hib, anti-PRP antibody titres of ≥0.15 mg/mL, ≥1 mg/mL and ≥5 mg/mL have been proposed as 
protective against short-term invasive disease, long-term invasive disease and colonization, respectively 
(62). 
There is evidence that the measured efficacy of conventional pertussis vaccines is higher against severe 
than against mild disease endpoints, and continued discussion over whether these vaccines are more 
protective against disease than against infection (63−64).
A major issue in the evaluation of polio vaccines is that IPV is less effective than OPV in protecting 
against enteric infection and transmissibility, although either may be equally effective in protecting against 
paralytic disease (65−67).
5.2 Exposure intensity/challenge dose
It may be possible to control infectious challenge doses to within a narrow range under 
laboratory conditions. However, this is not what occurs in human communities as there 
is likely to be considerable variation in exposure intensity both within and between 
populations. This heterogeneity of exposure is associated with factors such as whether 
exposure occurs within a home or other environment conducive to transmission, 
and individual social and hygiene behaviour. The risk of exposure to airborne or 
waterborne pathogens is likely to be higher in crowded and deprived settings with poor 
hygiene and sanitation compared to populations living in better conditions. 
5. Other issues related to 
immunological markers  
for protection
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This has important implications insofar as protection against a higher challenge 
dose or more frequent exposure is likely to require higher levels of immune response 
(e.g. higher levels of neutralizing serum antibodies). As a consequence, the level of 
protection provided by a specific antibody titre in one population or setting may be 
higher than that in a different population or setting in which higher or multiple challenge 
doses are more frequent. 
These factors have two implications for the relationship between protection and 
antibody titre, as illustrated in Figure 16. The slope or horizontal range of the curve 
is likely to be a function of the heterogeneity of exposure in a population, itself a 
function of environmental and socioeconomic heterogeneity. Its position along the 
horizontal axis will be a function of the average level of exposure in the population. 
These differences are illustrated by two curves, one (B) with a broad range or slope, 
indicating considerable within-population heterogeneity, in which an antibody titre of 
3 is associated with 70% protection, and another (A) with a narrower slope, indicating 
less within-population heterogeneity, in which an antibody titre of 3 is associated with 
greater – in this example 90% − protection. 
Figure 16. Hypothetical relationships between antibody titres and clinical 
protection in two populations with different intensities of exposure and  
different levels of heterogeneity
Population A – low exposure challenge dose, low heterogeneity
Population B – high exposure challenge dose, high heterogeneity
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EXAMPLE
Taranger et al. (31) reported that children with household exposure who escaped pertussis illness had a 
higher titre of anti-pertussis toxin IgG antibodies post-vaccination than those who escaped illness after 
only extra-household exposure. This means that if the logistic regression model proposed by Storsaeter 
et al. (46) were used in a setting in which most transmission occurred outside the household, the VE 
estimate would be higher than that obtained from a population in which most transmission occurs within 
the household.
These within- and between-population heterogeneities need to be considered before 
predicting the performance of a vaccine in a population based on a substitute endpoint 
derived in any particular context. Ideally, immune markers are needed that can be 
used reliably as a substitute for clinical protection across a range of settings (the level 
2 surrogate of protection described by Qin et al. (4)), or optimally in all settings. 
This is difficult to achieve, since many of the issues discussed in this report relate to 
heterogeneity between settings. The population, the pathogen strains and even the 
environment may be different, and these may influence the relationship between 
immunological markers and VE.
5.3 Host factors
Several host factors influence immune responsiveness as well as exposure doses, 
and hence may be expected to influence correlates of protection.
5.3.1 Age
Changes occur in the immune system over the course of the life span, exemplified 
by the acquisition and loss of passive immunity associated with maternal antibodies, 
maturation of immune competence in early childhood (which is for example relevant 
to the ability to mount a response to polysaccharide vaccines), repeated exposure to a 
wide variety of (sometimes cross-reactive) antigens throughout life, and progressive 
immunosenescence in old age. It is likely that for some pathogens, the components 
of the immune response important for protection (and thus predictive of VE) change 
quantitatively and qualitatively with age. 
EXAMPLE 
While it is commonly assumed that the efficacy of inactivated influenza vaccines is predicted by serum 
HI antibody titres, Gravenstein et al. (68) found that in a cohort of 408 nursing home residents aged 
≥65 years, 22 of those with high vaccine-induced HI titres (>1:640) still developed laboratory-confirmed 
influenza illness. A study of the efficacy of an inactivated influenza vaccine by McElhaney et al. (69) in the 
same cohort suggested that the CMI response might be a better predictor of protection against laboratory 
diagnosed influenza compared to humoral immunity. This evidence was based only on examination of 
the VE among older individuals (note - their immune response was not compared directly to younger 
individuals to assess whether CMI is also a better predictor of protection in a younger age group).
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5.3.2 Socioeconomic status
Since people from deprived socioeconomic backgrounds are more likely to live in 
crowded settings, socioeconomic status (SES) is associated with parameters that can 
affect the host response to the vaccine, such as nutritional status, exposure dose and 
frequency of exposure. As a result, the predictive value of a substitute endpoint may 
differ among persons from different settings or SES (as illustrated in Figure 16). 
EXAMPLE
A concentration of IgG anticapsular polysaccharide antibodies of ≥0.35 µg/ml one month after primary 
immunization was used for the licensing of PCV, based on pooled data from three trials (53, 70). In the 
individual trials, the antibody titre associated with protection was higher among infants more likely to be 
living in crowded and deprived settings, i.e. American Indian infants (≥0.99 µg/mL) and those enrolled in 
the trial carried out in Soweto, South Africa (≥0.68 µg/mL) compared to those living in northern California, 
USA (≥0.20 µg/mL). This heterogeneity in the antibody threshold is likely to be due to higher exposure 
dose among infants from more deprived settings. The recommended threshold (≥0.35 µg/mL) to assess 
pneumococcal VE could thus overestimate a vaccine’s efficacy in lower SES settings and underestimate 
efficacy in higher SES settings.
5.3.3 Environmental factors 
There are several instances in which vaccines perform very differently depending on the 
environment. This may be attributable to socioeconomic factors, but may also relate 
to climatic or other features of the environment.
EXAMPLES
There is much evidence that variations in BCG protection aganst tuberculosis are attributable at least in 
part to regional differences in exposure to environmental mycobacteria that share antigens with BCG or 
the tubercle bacilli, and either mask or block the action of the vaccine (71). 
The Gambian trial of pneumococcal conjugate vaccines noted that GMC antibody concentrations were 
significantly higher among those vaccinated in the rainy season (15).
5.4 Antigen factors
Most of the statistical methods used to predict VE based on substitute endpoints assume 
that the relationship between the immunological marker and clinical protection is 
similar among the vaccinated and unvaccinated groups. This assumption ignores the fact 
that any immunity observed in unvaccinated individuals may be derived from natural 
exposure to antigens that are not in the vaccine (i.e. from exposure to the pathogen itself, 
to related organisms or to other antigens in the environment that share epitopes with 
the infectious agent in question), and can thus be qualitatively and/or quantitatively 
different from that observed among those vaccinated.
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EXAMPLE
Live measles vaccines are attenuated strains of wild measles virus. Itoh et al. (72) discuss qualitative 
and quantitative differences between vaccine-induced and naturally acquired antibody response against 
measles in Japan. They showed that among children aged less than 10 years, those who had been 
vaccinated had significantly lower titres of measles neutralizing antibody than those who had experienced 
natural infection (mean titre ±SD: 4.8 ±1.5 versus 8.0 ±1.1, p<0.0001). They also found differences in the 
relationship between neutralizing and HI antibody activities: among those with similar levels of HI activity, 
vaccinated children had significantly lower neutralizing antibody titres than naturally infected children, 
indicating that there were qualitative differences between anti-measles antibodies produced after natural 
infection and after vaccination. It is unclear whether any such differences might be attributable to either 
attenuation of the vaccine virus or to the “unnatural” (intramuscular) presentation of vaccine-derived 
measles virus compared to wild virus. 
 Similarly, the immune response induced against an infectious agent may vary depending 
on the composition of the vaccine. For example, subunit vaccines comprise only part 
of a pathogen and will therefore elicit a different immune repertoire to that produced 
following natural exposure or vaccination with whole live or killed organisms.
EXAMPLES
Jelonek et al. (73) compared “natural” immunity from Hib exposure to that derived from four different 
vaccine formulations, a simple polysaccharide vaccine and three conjugate formulations that differed in 
composition and structure. They found that Hib vaccines yielded slightly different qualitative and quantitative 
antibody repertoires, and that each repertoire was different from the response elicited by natural infection. 
Findings from a study by Schlesinger et al. (74) suggested that antibodies induced by different anti-Hib 
conjugate vaccines had differing avidity; for instance, antibodies elicited by the HbOC formulation showed 
higher avidities and better bactericidal activity than the PRP-OMPC formulation. 
Antibody responses to pertussis vaccines depend on the antigens present in the particular vaccine (whole 
cell versus acellular, number of components), and their dosage (75). For instance, the antibody repertoire 
elicited by the 2-component (PT, FHA) and the 5-component vaccines (PT, FHA, PTN, and two types of 
FIM) are very different.
5.5 Immunological factors
5.5.1 Type of antibody
Most regulatory bodies prefer, whenever possible, to measure functional antibodies 
instead of total antibody level (which might include inactive antibodies). This provides 
biological plausibility for any association found between immunological markers 
and clinical protection, and increases confidence in the VE measures estimated 
using such markers as substitute endpoints. Examples of functional antibody assays 
include neutralizing antibodies (e.g. PRN for measles (5)), and bactericidal and 
opsonophagocytic antibodies (OPA) for polysaccharide vaccines (e.g. pneumococcal 
or Hib vaccines) (76−77). Thus, when assessing potential immune markers as substitute 
endpoints for VE, both qualitative and quantitative aspects of the immune response 
need to be considered. These include the avidity and bactericidal activity of an antibody 
and the association of titres of that antibody with the level of clinical protection.
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EXAMPLES
Saaka et al. (15) reported findings from a subgroup of children enrolled in an efficacy trial of 9-valent 
pneumococcal conjugate vaccine (which included serotype 1) in the Gambia. Most vaccinated children 
achieved a serotype 1-specific antibody level of >0.35 µg/mL (the WHO recommended threshold), and 
98% had a high ELISA geometric mean concentration (GMC) of >5 µg/mL. Surprisingly, the trial results 
were compatible with no protection induced by the vaccine against serotype 1 IPD (serotype 1-specific 
VE = -98% (95% CI -2090% - 72%). Although the number of events was small (4 cases of serotype 1 
IPD in the vaccinated versus 2 in the placebo), the authors conjectured that antibodies specific to this 
pneumococcal serotype could have had lower functional activity (e.g. low opsonophagocytic activity).
Schuerman et al. (78) showed that, although there was a correlation between serotype-specific OPA 
GMCs after vaccination with pneumococcal conjugate vaccine and protection against acute otitis media 
in young children, there was a lack of correlation between circulating IgG levels (measured by ELISA) 
for individual serotypes and clinical protection. 
5.5.2 Kinetics of the immune response
The measurement of any immunological marker is a snapshot, which needs to 
be interpreted in the light of the kinetics of the marker. Among several examples, 
Olin et al. and Kohberger et al. (47, 79, respectively) have both commented that the 
kinetics of antibody to pertussis vaccination may explain the lack of correlation between 
pertussis antibodies and clinical protection in some studies, particularly those that 
measured antibody responses very early after vaccination rather than at the time of 
later exposure. For hepatitis B vaccine, it has been shown that the anti-HB antibody 
titre rises to a peak after vaccination and then decreases progressively (25, 80−81). 
Analyses suggest that the post-vaccination peak titre could be the optimal antibody 
measure as a marker for protection against persistent infection. 
Unlike the hepatitis B example, antibody titres against some viruses appear to remain 
stable for a long time, even in the absence of boosting. For example, Amanna et al. (82) 
estimated, on the basis of data from a cohort of 45 adults, that the lower boundary of the 
95% CI for the half-lives of antibodies against rubella, measles, mumps, and hepatitis 
B virus were 114, 104, 90 and 63 years, respectively. 
Related to this is the issue of memory and the anamnestic response, whereby individuals 
can mount protective responses rapidly from a low background antibody titre level. 
Individuals with such vaccine-induced memory capability can in some circumstances 
be well protected despite a low antibody titre post vaccination or at the time of 
exposure.
Passive immunization and mother-to-child passive immunity transfer were discussed 
in Section 3 as possible means to identify potential candidate immunological markers 
of vaccine-induced protection. These study designs implicitly ignore the redundancy of 
the immune system and any potential cooperation between adaptive CMI and humoral 
immunity. This is further complicated by the fact that the kinetics of different arms of 
the immune system are likely to differ. 
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5.6 Measurement error and noise
Statistical methods assume that endpoints are measured accurately and do not account 
for measurement error. Non-systematic measurement error (e.g. arising from lack 
of standardization, laboratory variability or high intra-individual variability of the 
marker) can attenuate an association between a substitute endpoint and protection, 
and between the substitute endpoint and the vaccine. A consequence of this, for example 
in a Prentice-like validation, will be that adjustment for the substitute endpoint may 
fail to remove all the effect of the vaccine on the clinical endpoint. Thus an important 
component of the search for immune correlates is assay validation studies and selection 
of assays with the lowest ‘noise’. 
Among the tools used to investigate the reliability of measurements and the contribution 
of intra- and inter-individual variations is the intra-class correlation coefficient (ICC). 
In theory, the inter-individual variation should be greater than the intra-individual 
variation in order for a substitute endpoint to be useful. Intra-individual variation may 
be linked to factors such as the kinetics of the immune marker (short or long-term 
fluctuation over time) and the reliability of the assay. Various approaches are used to 
reduce intra-individual variation, including taking repeated measurements at different 
times and/or repeated samples at approximately the same time, using identical storage 
methods for samples, and standardized assays. Most of the inter-individual variations 
observed in the immune response are expected to be explained by the effect of the 
vaccine, but residual variation may arise due to differences among individuals in their 
nutritional status, genetic traits, intensity and frequency of pathogen exposure, etc. 
The residual variation can be minimized by randomization in a trial or by adjustment 
and other methods for control of confounding in observational studies (83).
Assays used to measure potential immunological markers of vaccine-induced protection 
may give different results depending on the laboratory in which the samples are 
processed. The need for valid and reliable assays is thus emphasized by regulatory 
agencies. 
EXAMPLE 
WHO recommends measurement of the opsonophagocytic activity of vaccine-induced antibodies as a 
criterion for pneumococcal conjugate vaccine licensure. It was acknowledged at a recent WHO workshop 
(84) that the opsonophagocytic activity assays are not yet sufficiently standardized. 
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6.1 Interpretation of vaccine-induced protection: ‘all-or-none’ versus 
‘partial’ models
When a subject gets complicated, it is sometimes useful to go back to the initial 
questions. What is meant by a vaccine conferring 80% protection against a specific 
clinical endpoint, and how does this relate to levels of immune markers that may 
be used as substitute endpoints? Smith et al. (85) proposed two models of vaccine 
action, termed all-or-none (according to which an efficacy of 80% implies that 80% of 
vaccine recipients are totally protected, and the remaining 20% not at all protected) or 
partial (whereby all recipients of the vaccine have their incidence rate reduced by 80% 
compared to non-vaccinees). The initial paper emphasized the implications of these 
two models for the measurement of VE using observational studies. This distinction 
has since been discussed by several authors, some of whom have used the term “leaky” 
to describe the partial model of Smith et al. (86−88).
This perspective provides an opportunity to tie together several of the themes introduced 
above, by relating the presumed mode of action of vaccines to immune markers, clinical 
endpoints and VE. It is important to note that the models were initially proposed 
from an epidemiological perspective – reflecting what is observed in terms of risks of 
outcome among vaccinees and non-vaccinees over time in populations. Interpretation 
of these models brings together several issues, including: (a) what the vaccine does to 
the immune response, (b) the implications of various immune responses for protection, 
and (c) the implication of variations in challenge dose in the community.
6.1.1 All-or-none model of action 
This model assumes that a certain proportion (VE %) of vaccine recipients reach 
a threshold level of (for example) antibody titre and are fully protected against the 
disease, and that all the remaining (100–VE%) are not protected at all – they remain 
as susceptible as those who had not been vaccinated. There are at least two ways to 
conceive of this circumstance, described in A and B below.
All-or-none model A
The most straightforward interpretation of this model is to consider the relationship 
between the antibody level and protection as a simple step function, with 0% protection 
up to a threshold antibody titre and 100% protection thereafter, as discussed in Section 
4.2.2 and shown in Figure 17A. The vaccine is assumed to raise a proportion (VE %) 
of vaccinees above this threshold. 
6. Putting it together – 
the relationship between 
immunological markers and  
vaccine performance in the field
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All-or-none model B
An alternative interpretation of the all-or-none model is to suppose that the relationship 
between antibody titre and protection is step (or sigmoid) in shape and that individuals 
with high titres are completely protected, but that the vaccine’s effect on recipients is 
distinctly bimodal, such that the immune response of a proportion (VE %) of vaccinees 
is lifted to the higher level associated with complete protection, and the vaccine has no 
effect on the remaining 100−VE% of vaccinees. This is illustrated in Figure 17B. 
The important point with either interpretation is that a certain proportion (VE %) of 
vaccinees are fully protected, and the remaining 100–VE% are not protected at all by 
the vaccine. This is illustrated in Figure 17C, in which the goblets represent vaccinated 
individuals, and the liquid in each goblet represents the level of protection. The array 
indicates that 75% of the vaccinated individuals are fully protected and 25% of them 
are not protected at all. Thus, VE is 75%.
Figure 17. Relationship between log antibody titre and clinical protection if 
challenged in an all-or-none model 
probability of 
protection
distribution of 
antibody titres
A.
probability of 
protection
distribution of 
antibody titres
B. C.
 Distribution of log antibody titres among vaccinees: unimodal (A, bottom line), bimodal (B, bottom 
line).
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In the first interpretation, the step threshold may be considered a simple correlate – 
or surrogate – of protection. In the second, the correlate could in theory be any titre 
which separates the fully-protected vaccinees from the remaining (unprotected) vaccine 
recipients. These two antibody titre thresholds may be close to what Plotkin (89-90) 
calls “absolute correlates of protection”. He gives examples, including vaccines against 
diphtheria, tetanus, measles, rubella, hepatitis A and Lyme disease. 
It may be that a circumstance such as illustrated in Figure 17A is unlikely for many 
pathogens. A unimodal distribution of antibody titres among vaccinees and a simple 
step threshold between no and full protection seems biologically less plausible than 
the sort of circumstance illustrated in Figure 17B.
If the all-or-none model were to hold, the antibody titre threshold could be considered 
as a quantitative substitute for protection and used for licensure of a vaccine. Once the 
threshold has been determined, the VE measured using this substitute endpoint could 
be estimated by comparing the proportion of individuals below this threshold in the 
vaccinated group to that of the placebo group (as in Section 4.2.2, equation 2). Protective 
antibody titres for several vaccines, including pneumococcal and meningococcal C 
conjugate vaccines, have been derived using methods that in effect assume that the 
vaccine mechanism corresponds to an all-or-none model.
This perspective ignores whether or not the immune marker is actually on a causal 
pathway. If an all-or-none mechanism is accepted, with perfect correlation between an 
immune marker and observed clinical protection, the association should allow strong 
inferences for licensure purposes – regardless of whether the immune marker is itself 
involved in protection.
6.1.2 Partial (‘leaky’) models 
According to this model, the risk of infection/disease in all vaccinees is reduced 
(by VE %) compared to non-vaccinees, none of the vaccinees being fully protected. 
The assumption that no vaccinee is totally or permanently protected implies one or 
both of the following:
No amount (titre) of the immune marker is totally protective or, if it is, no i) 
individual can maintain that titre for a long period (because of waning or transient 
immunosuppression);
The degree of protection is a function of the level of the immune marker – the ii) 
simplest explanation being that protection is a function of both the level of the 
immune marker and the challenge dose.
Two interpretations follow:
Partial/leaky model A
According to this interpretation, protection is a step function such that those above some 
immune marker threshold have their risk reduced by VE % compared to those below 
the threshold – and the vaccine succeeds in raising all vaccinees above this threshold. 
As illustrated in Figure 18, partial (75%) reduction of disease risk is attained at antibody 
titres above a threshold of approximately 2.0. The goblets indicate a circumstance 
in which all vaccinated individuals are 75% protected. In this simplest description, 
the threshold antibody level is sufficient to protect against VE % of challenge doses in 
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the population. In theory, if follow-up were to continue a very long time, all vaccinees 
will ultimately be exposed to a higher challenge against which the above-threshold 
antibody cannot protect, and thus everyone will ultimately contract the outcome / 
illness. 
Figure 18. Relationship between antibody titre and  
 the probability of protection in a partial model
 
probability of 
protection
distribution of 
antibody titres
Partial/leaky model B
According to this interpretation, the level of protection is a function of the antibody 
level over a range of antibody titres induced by the vaccine. In this situation, 
overall VE may be interpreted as an average reduction in risk of disease among 
vaccinated compared to unvaccinated individuals. This is illustrated in Figure 19, 
which corresponds to Dunning’s scaled logit model (59) mentioned in Section 4.2.3; 
it is possible to use the knowledge of the probability of disease to different levels of the 
immune response to estimate VE correctly. As with partial/leaky model A, no one has 
100% protection and so in theory all will ultimately succumb to the clinical outcome 
if followed for long enough. 
Figure 19. Relationship between log antibody titre and clinical protection  
if challenged and the distribution of log antibody titres among v 
accinees in an alternative partial model 
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 The goblets represent a vaccinated population with increasing levels of protection up to 85% protection. 
Partial protection models have interesting properties. According to the model B 
interpretation, those with the lowest levels of antibody induced by the vaccine, 
and hence with the least vaccine-induced protection, should contract the infection 
more rapidly than those with the higher levels of antibody and protection, and hence 
one expects observed protection to increase over time.
6.1.3 Summary 
Although the all-or-none and partial/leaky models provide useful perspectives, 
it is likely that neither describes well what really happens, and that a variety of hybrid 
mechanisms apply in the real world. For example, there may be circumstances in which 
some individual vaccinees are not at all affected by the vaccine (their goblets remain 
empty), but others respond in various ways giving them different levels of protection. 
This might be viewed in terms introduced in Section 1.1.2: some achieve complete 
protection (the full goblet – protection against any challenge), some achieve incomplete 
protection (partially full goblets, implying protection against low or moderate, 
but not against high challenge doses); and some achieve no protection at all (the empty 
goblet, effectively no different from a non-vaccinee). 
This perspective may be most useful in clarifying the importance of heterogeneity – 
both in terms of immune response among vaccinees (represented by the frequency 
distributions of titres in Figures 12, 16, 17, 18, 19) and in terms of protection (represented 
by the various sigmoid curves in Figures 12, 13, 16, 18, 19). Heterogeneity of immune 
response will be largely a function of the vaccine product, the genetic background, 
and prior immune experience of the vaccinee. Heterogeneity of protection will be 
determined largely by epidemiological factors influencing exposure intensity or 
environmental factors – illustrated in this document by pneumococcus and pertussis, for 
which intensity of exposure appears to be key, and tuberculosis, for which environment 
is also key.
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It is implicitly assumed in many conventional interpretations of protective immunity 
and vaccine action that heterogeneity is not important. Fortunately, this may be the 
case for some vaccines and infections, e.g. measles and others with relatively clean 
correlates of protection, but for others this may explain much of the difficulty in vaccine 
evaluation (e.g. for tuberculosis or pertussis). Such heterogeneity complicates the issue 
of predicting protection as a function of immunological measures. 
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The use of immunological markers as substitute endpoints for vaccine evaluation is 
important, but complicated. It is not straightforward to identify such markers or to 
ensure that the estimated VE derived from their use predicts accurately the vaccine 
effectiveness that would have been observed if the clinical endpoints were recorded. 
Differences between infectious agents, vaccines, immune responses and population 
contexts provide many opportunities for heterogeneities and complex relationships. 
It is intuitively reasonable that a vaccine’s effectiveness in protecting against an infection 
or disease outcome will be a function of several things: the prior immunological status 
of the vaccine recipient; the immune response to the vaccine (described in terms of the 
proportions of individuals who respond in a particular way to any given degree); the 
implications of different levels and combinations of immune response for protection 
against various exposures; and the actual patterns and levels of exposure in the vaccinated 
community. These several influences are brought together in considering the various 
models of vaccine action, as described in Section 6. 
For regulatory purposes, it may not be necessary to contemplate all the factors that can 
influence effectiveness, but to concentrate on two: the effect of the vaccine in terms of 
induced immune response, and the implications of these responses for clinical protection 
under some standard circumstances. Despite the methodological challenges outlined in 
this paper, experience is accumulating with reference to many infections and vaccines, 
which is considered sufficient to allow licensure on the basis of phase II immunogenicity 
studies and prior knowledge on effectiveness of related vaccines. 
Epidemiologists involved in vaccine evaluation also need to be aware of the broader 
subtleties of vaccine responses and effects (issues of indirect protection and herd 
immunity, e.g., are not discussed in this paper). Smith et al. pointed out that time trends 
in observed effectiveness (apparent efficacy) of vaccines are influenced by whether an 
all-or-none or partial immunity model is appropriate, and these, in turn, determine 
what incidence statistic or control group should be employed in cohort or case−control 
studies to evaluate efficacy, respectively (85). Such subtleties have rarely been applied 
in practice to date, but they hold the opportunity for careful epidemiological studies 
to provide insights into the mechanism of action of vaccines. 
Much work remains to be done. Indeed, this is a subject ripe for serious collaboration 
between immunologists, statisticians, epidemiologists and regulatory vaccinologists. 
7. Conclusions
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The terms correlate and surrogate of protection are used widely but inconsistently 
in the literature, including by regulatory agencies and prominent authorities. 
Examples from regulatory agencies include the following.
US Food and Drug Administration (FDA) 
Surrogate endpoint: “Laboratory or physical sign that is used in therapeutic trials as a 
substitute for a clinically meaningful endpoint that is the direct measure of how a patient 
feels, functions or survives and that is expected to predict the effect of the therapy” 
(57 FR 13234-13235 4/15/92) (91).
Correlate of protection: “Generally, a laboratory parameter that has been shown to be 
associated with protection from clinical disease” (Tiernan, 92). 
Accelerated approval of vaccines by the FDA can be granted if well-controlled trials 
have shown that a surrogate endpoint is considered “reasonably likely” to predict 
clinical benefit, subject to the requirement that the applicant studies the vaccine further 
to demonstrate clinical benefit (Norman Baylor, Global Vaccine Research Forum, 
Bamako, Mali, December 2009). This indicates flexibility in the definition of a surrogate 
endpoint so that the FDA can use expert judgement in specific circumstances.
International Conference on Harmonization (ICH): European Union, 
Japan and USA tripartite guidelines
Validated surrogate endpoint: “an endpoint which allows prediction of a clinically 
important outcome but in itself does not measure a clinical benefit. When appropriate, 
surrogate outcomes may be used as primary endpoints.” The strength of evidence for a 
surrogate includes consideration of: “(i) the biological plausibility of the relationship, 
(ii) the demonstration in epidemiological studies of the prognostic value of the surrogate 
for the clinical outcome and (iii) evidence from clinical trials that treatment effects on 
the surrogate correspond to effects on the clinical outcome” (ICH, 93−94).
European Agency for the Evaluation of Medicinal Products (EMEA) 
Serological surrogate: “a predefined antibody concentration correlating with clinical 
protection”. 
Immunological correlate of protection: “...e.g. specific antibody titre correlating with 
protection...” (95).
Annex 1:  
Correlate and surrogate 
terminology 
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The definitions described in the above three examples have been adopted or modified 
by other agencies. For example, the EMEA definition of a serological surrogate was 
used in the WHO guidelines on clinical evaluation of vaccines (96). 
The inconsistency in these definitions is accentuated by differences in the choice 
of the factor for which substitutes are sought. This is illustrated by contrasting the 
following definitions proposed by Plotkin (89-90) and by Qin et al. (4) for use in 
vaccine research.
Comparison of definitions of correlates and surrogates of protection
Plotkin (2008) Qin et al. (2007) 
Correlate of 
protection / risk
Immune response closely related to 
protection / that provides protection
Immune response whose presence 
is associated with low risk of disease/
infection
Surrogate of 
protection
Immune response that is not in itself 
protective, but which substitutes for the 
true correlate 
Correlate that predicts accurately the 
level of VE, i.e. for which it can be shown 
that it is responsible for protection
Plotkin2 (89-90) considers a substitute for the protective immune response. He calls 
this substitute a surrogate of protection, defined as “a quantified specific immune 
response to a vaccine that is not in itself protective but that substitutes for the true 
(perhaps unknown) correlate”. He calls the protective immune response itself a correlate 
of protection, defined as “a specific immune response to a vaccine that is closely related 
to protection against infection, disease, or other defined end point”. 
In contrast, Qin et al.3 (4) focus on substitutes for clinical protection; they consider 
substitute endpoints that are ideally surrogates of protection. They define a correlate 
of risk as “an immunological measurement that correlates with the rate or level of a 
study end point used to measure VE in a defined population”. On the other hand, a 
surrogate of protection is “a correlate of risk that reliably predicts a vaccine’s level of 
protective efficacy on the basis of contrasts in the vaccinated and unvaccinated groups’ 
immunological measurements”. 
It appears that these important authors differ in their perspectives, and that 
Plotkin’s use of “correlate” approximates Qin’s use of “surrogate”. Their examples 
illustrate these different perspectives. For instance: Plotkin calls a PRN antibody titre 
of ≥120 mIU/mL a correlate of protection against measles (PRN antibodies are directly 
involved in the neutralization of the virus and therefore have a direct causal role in 
protection). On the other hand, he describes serum IgA against rotavirus as a surrogate 
for mucosal IgA, which he in turn calls a correlate because mucosal IgA is responsible 
for protection against colonization of the gut by rotavirus, not serum IgA. In contrast, 
Qin et al. note that serum antibodies to capsular polysaccharide of H. influenzae type b vaccine 
are correlated statistically to the risk of meningitis (and thus provide a good correlate 
of risk), but that the relationship between meningitis incidence and the antibody 
concentration is different in vaccinees and non-vaccinees. Specifically, antibody 
concentrations of ≥0.15 µg/mL predict low incidence in non-vaccinees whereas 
concentrations of ≥1 µg/mL are needed to predict equally low incidence in vaccinees, 
thus invalidating this correlate of risk as a surrogate of protection.  
2 Plotkin uses the term “correlate of protection”;
3 Qin et al. use the term “correlate of risk”
47WHO/IVB/13.01
Other statistical definitions exist. For example, Prentice defined a surrogate endpoint 
as “a response variable for which a test for the null hypothesis of no relationship to 
the treatment groups under comparison is also a valid test of the corresponding null 
hypothesis based on the true endpoint” (3). Qin et al. define criteria for a principal 
surrogate of protection using a framework of causal inference, namely: “(i) groups of 
subjects with no or the lowest vaccine effect on the immune response have no vaccine 
efficacy and (ii) groups of subjects with a sufficiently large vaccine effect on the immune 
response have positive vaccine efficacy” (4).
Some authors have used the terms individual- and population-based correlates of 
protection with reference to those derived from (i) follow-up of entire vaccinated 
populations with known immune marker titres (called “individual-based”) or (ii) derived 
from frequency distributions of samples of vaccinated and unvaccinated populations 
(called “population-based”) (54). 
To sum up, the definitions used to describe immune markers as substitute endpoints to 
evaluate vaccine efficacy are not universally agreed. There are differences in the usage 
of the terms correlate and surrogate of protection. In this report, the term correlate is 
favoured to describe markers that are statistically associated with clinical protection, but 
are not necessarily on the causal pathway leading to protection; and the term surrogate 
to refer to markers that lie on the causal pathway leading to protection. This is thus 
closer to Qin et al. (4) than to Plotkin (89-90) in terminological preference. 
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